The patent allowance strengthens Silo's intellectual property position for SPC-15, but the asset remains in development with no clinical data or regulatory milestones disclosed. Monitor for future clinical trial initiations or partnership announcements that could provide a clearer catalyst.
Price Chart
Executive Summary
Silo Pharma announced that the USPTO has issued a Notice of Allowance for a patent covering its lead asset SPC-15, an intranasal therapeutic for PTSD. The allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses, and a corresponding patent was previously issued by the Japan Patent Office. This is a positive intellectual property milestone for a developmental-stage biotech, but it does not change the company's pre-revenue status or near-term financial trajectory.
Key Facts
- USPTO issued a Notice of Allowance for a patent application covering SPC-15, Silo's lead intranasal therapeutic for PTSD.
- The allowed patent covers composition and method claims for preventing or delaying stress-induced behavioral responses.
- A corresponding patent was issued by the Japan Patent Office earlier in 2026.
- Silo Pharma is a developmental-stage biopharmaceutical company with no approved products or disclosed revenue.
- The company's pipeline includes SPC-15 (PTSD), SP-26 (fibromyalgia/chronic pain), and a preclinical Alzheimer's asset.
Financial Impact
No financial figures disclosed; the company is pre-revenue and developmental-stage.
Risk Factors
- SPC-15 is still in preclinical or early clinical development; no FDA approval or commercialization timeline provided.
- Silo Pharma has no approved products or revenue, making it highly dependent on future financing and development success.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364696 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $1.20 | awaiting T+60 | — | $1.16 (−3.33%) |
Oct 2, 2026 24d ago | 8-K | $1.49 | awaiting T+60 | — | $1.16 (−22.15%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | — | $1.16 (−36.96%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | — | $1.16 (−68.94%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.16 (−77.39%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.16 (+81.32%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.16 (−81.01%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.16 (−76.75%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.16 (−82.78%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.16 (−83.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers